捷克国家银行将Vertex制药公司的股份提升至62 770股,价值2 790万美元,因为该公司在Q2上收入丰厚。 The Czech National Bank boosted its Vertex Pharmaceuticals stake to 62,770 shares, worth $27.9 million, as the company posted strong Q2 earnings.

捷克国家银行将Vertex制药公司的股份增加了3 790股,使其总股份达到62 770股,价值2 790万美元。 The Czech National Bank increased its stake in Vertex Pharmaceuticals by 3,790 shares, bringing its total to 62,770 shares valued at $27.9 million. 该生物技术公司报告Q2结果强劲,EPS为4.52美元,粗略估计为2.8美元,收入为29.4亿美元,比上一年增长11.3%。 The biotech firm reported strong Q2 results with EPS of $4.52, beating estimates by $0.28, and revenue of $2.94 billion, up 11.3% year-over-year. 其库存有50天移动平均421.34美元,物价与收益比率为28.11。 Its stock has a 50-day moving average of $421.34 and a price-to-earnings ratio of 28.11. Vercity Capital将其持有量减少了5.1%,而战略倡导者有限公司购买了565个Vertex公司(一家税收技术公司)的股份,将其股份增加了9.6%。 Veracity Capital reduced its holding by 5.1%, while Strategic Advocates LLC bought 565 shares of Vertex, Inc., a tax technology company, increasing its stake by 9.6%. Vertex Inc.报告EPS为0.15美元,高于估计数0.14美元,收入增长14.6%。 Vertex, Inc. reported EPS of $0.15, up from a $0.14 estimate, with 14.6% revenue growth. 分析员预计今年的EPS费用为0.38美元。 Analysts expect $0.38 EPS for the year.